The specter of generic rivalry has consistently loomed over copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the future of similar medicinal stakes. While early times saw significant gains, the patent lapse has opened the way for cheaper alternatives, potentially reducing profitability and presenting a real danger for invest… Read More